Posted April 2, 2015
The IFOPA is pleased to share news that Clementia Pharmaceuticals advances Phase 2 Clinical Trial of Palovarotene in patients with Fibrodysplasia Ossificans Progressiva (FOP) based on recommendations from Data Monitoring Committee (DMC). To download and read the entire announcement please click on Clementia DMC Press Release April 2015.
Read other information about the palovarotene clinical trial.
